Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004)

Página do item simplificado
dc.contributor.authorScheinberg, Morton Aaron [UNIFESP]
dc.contributor.authorHamerschlak, N.
dc.contributor.authorKutner, J. M.
dc.contributor.authorRibeiro, AAF
dc.contributor.authorFerreira, E.
dc.contributor.authorGoldenberg, José [UNIFESP]
dc.contributor.authorKiss, M. H.
dc.contributor.authorChahade, W. H.
dc.contributor.institutionHosp Israel Albert Einstein
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionHosp Servidor Estado Sao Paulo
dc.date.accessioned2018-06-15T16:52:41Z
dc.date.available2018-06-15T16:52:41Z
dc.date.issued2006-01-01
dc.description.abstractObjective Rituximab, a monoclonal antibody against B-lymphocytes that express CD 20, is already available for the treatment of non-Hodgkin's lymphoma. Due to the increased relevance of B-cell regulation in the pathogenesis of autoimmune diseases, rituximab is being used in the treatment of patients whose condition is refractory to conventional therapy.Methods We retrospectively evaluated the short-term efficacy and tolerance of rituximab in patients with various autoimmune diseases who were treated at the Hospital Israelita Albert Einstein in the city of Sao Paulo.Results During the period 2002-2004, 29 patients with various autoimmune diseases were treated with rituximab 375 mg/m(2) for 4 consecutive weeks, or two doses of I g 2 weeks apart. We observed remarkable short-term results in all cases, except for one patient with thrombocytopenic purpura. Of note, we describe the results in two patients with diseases not previously treated with rituximab (hypergammaglobulinemic purpura of Waldenstrom and eosinophilic fasciitis with hypergammaglobulinemia). Treatment was well tolerated, with no unexpected adverse events. We also observed a marked reduction in steroid dosage.Conclusion Rituximab seems to be safe and effective in the treatment of patients with a variety of autoimmune diseases that are refractory to other modalities of treatment.en
dc.description.affiliationHosp Israel Albert Einstein, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Sao Paulo, Brazil
dc.description.affiliationUniv Sao Paulo, Sao Paulo, Brazil
dc.description.affiliationHosp Servidor Estado Sao Paulo, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent65-69
dc.identifierhttp://www.clinexprheumatol.org/article.asp?a=2790
dc.identifier.citationClinical And Experimental Rheumatology. Pisa: Clinical & Exper Rheumatology, v. 24, n. 1, p. 65-69, 2006.
dc.identifier.issn0392-856X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/43311
dc.identifier.wosWOS:000236018300011
dc.language.isoeng
dc.publisherClinical & Exper Rheumatology
dc.relation.ispartofClinical And Experimental Rheumatology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectarthritisen
dc.subjectautoimmune diseasesen
dc.subjectB-lymphocytesen
dc.subjectlupus erythematosusen
dc.subjectthrombocytopenic purpuraen
dc.subjectrituximaben
dc.titleRituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004)en
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos